About This Comparison
Our Editorial Standards
This weight loss provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, service areas, and verified customer reviews.
Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.
Zepbound vs Wegovy: The Weight-Loss Injectable Comparison
Zepbound and Wegovy are the two branded injectables the FDA has approved specifically for chronic weight management, and they are the weight-labeled siblings of the diabetes drugs Mounjaro and Ozempic. Zepbound is tirzepatide, a dual GIP and GLP-1 agonist; Wegovy is semaglutide, a GLP-1 agonist. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine, settled the effectiveness question directly: Zepbound produced 20.2% average body weight loss versus Wegovy 13.7% at 72 weeks. But effectiveness is only one axis. Wegovy holds published cardiovascular outcomes data from the SELECT trial that Zepbound has not yet matched, sits at a lower self-pay price through NovoCare, and both differ in their secondary approvals and coverage patterns. This comparison covers the trial results, the safety and coverage differences, and the real 2026 pricing, so you can weigh maximum weight loss against heart-protection evidence and cost.
Effectiveness: Zepbound Leads
Where Wegovy Counters: Heart Data and Price
Which Should You Choose?
Frequently Asked Questions
Is Zepbound more effective than Wegovy?
Yes, on weight loss, and the evidence is direct. The SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine tested both drugs in the same patients under identical conditions for 72 weeks and found Zepbound (tirzepatide) produced 20.2% average body weight loss versus Wegovy (semaglutide) 13.7%, a roughly 6.5-point gap that means about 15 extra pounds for a 240-pound starting weight, with more Zepbound patients hitting the deeper 15% and 20% thresholds. The dual-hormone mechanism, adding GIP to the GLP-1 action, drives the difference. Two honest qualifiers: averages hide wide individual variation, so a strong Wegovy responder can outperform a weak Zepbound responder, and Wegovy holds one advantage Zepbound does not, published cardiovascular outcomes data showing a 20% reduction in heart events in the SELECT trial. So Zepbound is more effective for weight loss specifically, but Wegovy may be the better choice for someone whose primary concern is documented heart protection, and both are far more effective than any pre-2021 weight-loss medication.
Which is cheaper, Zepbound or Wegovy?
For self-pay patients at maintenance doses, Wegovy is often cheaper. Wegovy costs $499 per month flat through the NovoCare Pharmacy direct channel regardless of dose. Zepbound through LillyDirect vials starts lower at $349 for the 2.5mg starting dose but rises to $499-$699 at the higher maintenance doses most patients reach through standard titration, so once you are past the starting weeks, Wegovy flat $499 frequently undercuts Zepbound. Retail list prices favor Zepbound slightly ($1,086 versus $1,350), but almost nobody should pay retail given the direct channels. With insurance coverage, the comparison collapses: covered patients with manufacturer savings cards pay as little as $25 per month for either drug, which is why checking your formulary matters more than comparing self-pay prices. And if branded pricing is out of reach entirely, compounded semaglutide (the same molecule as Wegovy) runs $99-$227 per month through telehealth programs, the budget lane Zepbound lacks since compounded tirzepatide lost its legal basis in 2025. HSA and FSA funds apply to all legitimate routes.
What is the difference between Zepbound and Wegovy besides the drug?
Beyond the active ingredients (tirzepatide in Zepbound, semaglutide in Wegovy), the meaningful differences are their evidence bases, secondary approvals, and pricing. Effectiveness: Zepbound produced more weight loss head-to-head (20.2% versus 13.7%). Heart data: Wegovy has published cardiovascular outcomes showing a 20% reduction in major cardiac events (the SELECT trial), which Zepbound has not yet matched for the weight-loss population. Secondary approval: Zepbound gained an obstructive sleep apnea indication in December 2024 that opens coverage pathways for OSA patients, while Wegovy carries a cardiovascular risk-reduction indication reflecting its SELECT data. Price: Wegovy is $499 flat through NovoCare; Zepbound vials run $349-$699 by dose. Both share the same GLP-1 side-effect profile, the same serious-but-rare risks, and the same weight-regain-after-stopping reality. Their diabetes siblings differ too, Wegovy pairs with Ozempic, Zepbound with Mounjaro, which matters if your diagnosis is diabetes rather than obesity. The practical decision comes down to insurance coverage first, then whether maximum weight loss, heart protection, or sleep apnea treatment is your priority.
Can I switch from Wegovy to Zepbound or vice versa?
Yes, switching between the two is common and clinically routine, most often from Wegovy to Zepbound when a patient plateaus or wants the greater weight loss the head-to-head data supports, though the reverse also happens over cost, insurance changes, or a desire for Wegovy heart-protection data. Providers typically transition directly, starting the new drug at a low-to-mid dose rather than the very bottom of its titration ladder, adjusted for how much of the previous drug you were taking, and there is no required washout period, though your provider will time the first new dose against your last previous injection. Set realistic expectations: switching helps many plateaued or non-responding patients, but it is not guaranteed, since some of a plateau reflects physiology common to both drugs and to weight loss generally. Because the two titration schedules do not map one-to-one, this is a prescriber-managed change, not a self-directed swap. If cost rather than effectiveness drives your switch, also consider that compounded semaglutide offers the Wegovy molecule at $99-$227 per month, which may solve the budget problem without changing the underlying medication.
Do Zepbound and Wegovy have the same side effects?
Largely yes, because both act on the GLP-1 pathway that slows stomach emptying. The gastrointestinal profile is shared: nausea most commonly, then vomiting, diarrhea, and constipation, concentrated during the dose-escalation weeks and easing as your body adapts. In the SURMOUNT-5 head-to-head, side-effect rates were broadly similar between the two despite Zepbound producing substantially more weight loss, which some read as mildly favorable for Zepbound tolerability relative to its effect. The serious-but-rare risks are identical: pancreatitis, gallbladder disease that rapid weight loss itself can trigger, and the thyroid C-cell tumor warning that excludes anyone with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Neither is used in pregnancy. Both also share the non-drug realities of rapid weight loss: muscle loss that makes protein intake and resistance training important, and weight regain after discontinuation that makes maintenance planning essential. Management is the same for both: slow titration, smaller and lower-fat meals during escalation, hydration, and working with your prescriber on dose adjustments rather than quitting when side effects appear.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards